Form 4: Tenaya CEO Sells Shares for Tax Obligations

Tenaya Therapeutics CEO Faraz Ali sold common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• CEO Faraz Ali sold a total of 14,533 shares of Tenaya Therapeutics, Inc. common stock on August 18, 2025.
• The sales were executed at a weighted average price of $1.253 per share, with individual transaction prices ranging from $1.18 to $1.32.
• These transactions were specifically undertaken to cover tax withholding obligations arising from the vesting of restricted stock units (RSUs) awarded on February 15, 2023, February 23, 2024, and February 6, 2025.
• Following these transactions, Ali Faraz beneficially owns 302,792 shares of common stock, which includes 219,881 shares that will be issued upon vesting of restricted stock units.

Sentiment

Score: 7

Explanation: The filing reports routine 'sell to cover' transactions by the CEO for tax purposes related to RSU vesting. This is a neutral to slightly positive event as it indicates equity compensation is vesting, and the sales are non-discretionary, not signaling a lack of confidence. The CEO retains significant beneficial ownership.

Positives

• The sales are non-discretionary, specifically for tax withholding, indicating no change in management's underlying confidence in the company.
• The CEO continues to hold a substantial number of shares, including a significant portion of unvested restricted stock units, aligning his interests with shareholders.

Negatives

• The sale of shares, even for tax purposes, reduces the direct ownership stake of the CEO.
• The sale price of $1.253 per share is relatively low, potentially reflecting current market valuation.

Future Outlook

NA

Industry Context

This type of 'sell to cover' transaction is a standard practice across all industries, including biotechnology, for executives to manage tax liabilities associated with equity compensation vesting. It does not typically reflect a change in strategic direction or operational performance.

Comparison to Industry Standards

• These transactions are routine for executives receiving equity compensation. Compared to industry standards, the sale of shares to cover tax obligations upon RSU vesting is a common and expected event, not indicative of a negative outlook on the company's prospects.
• Many executives at comparable biotech firms like CRISPR Therapeutics (CRSP) or Editas Medicine (EDIT) engage in similar transactions when their equity awards vest.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO for tax purposes is a routine event and does not typically signal a change in company fundamentals or management's long-term view. The CEO's continued significant beneficial ownership aligns his interests with shareholders.

Key Dates

Recommendation

The filing is a routine Form 4 detailing 'sell to cover' transactions by the CEO for tax obligations related to RSU vesting. These are non-discretionary sales and do not reflect a change in the CEO's confidence or the company's operational performance. The CEO retains substantial beneficial ownership, aligning his interests with shareholders. Therefore, this filing alone does not warrant a change in investment recommendation; a 'hold' stance is maintained pending further operational or financial updates.

Keywords

Tenaya Therapeutics, TNYA, SEC Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, CEO, Faraz Ali, Biotechnology, Pharmaceuticals